Abstract
Recent analyses of series of small-cell lung cancer (SCLC) patients included in clinical trials have shown improved survival over time, but it has been impossible to determine whether this was due to selection biases, stage migration, or true therapeutic improvement. To determine if there has been a true improvement of survival over time, we reviewed the medical records of all consecutive patients diagnosed with SCLC between 1981 and 1994 in the Bas-Rhin in France. Among the 787 patients (median age 63), there was no significant period effect for sex, age, or stage. Staging work-ups became increasingly thorough (significant period effect). The mean number of investigations and of tumour sites detected correlated significantly. The chemotherapy rate increased (from 76.4% in 1981–1983 to 91.7% in 1993–1994, P = 10–5) and mediastinal irradiation decreased (to roughly 25% of patients after 1983). Median survival time increased for the overall population from 6.6 months in 1981–1983 to 11.3 months in 1993–1994 (P = 10–5), for patients with limited disease (LD) from 9.2 (P = 0.002) months to 14.0 months, and for those with extensive (ED) disease from 3.5 months to 9.6 months (P = 10–5). Significant independent prognostic factors were disease extent, clinical trial participation, period, type of chemotherapy, and mediastinal irradiation in LD. Survival time has truly improved as ‘state of the art’ management of SCLC has changed. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Aisner J, Allort P and Bitran J et al (1983) Role of chemotherapy in small-cell lung cancer: a consensus report of the International Association for the Study of the Lung cancer workshop. Cancer Treat Rep 67: 37–43
Albain KS, Crowley JJ and Leblanc M et al (1990) Determinants of improved outcome in small-cell lung cancer: an analysis of 2580 patients: Southwest Oncology Group Data Base. J Clin Oncol 8: 1563–1574
Antman K, Amato D and Wood W et al (1985) Selection bias in clinical trials. J Clin Oncol 3: 1142–1147
Armitage P (1971). Statistical Methods in Medical Research. Blackwell: Oxford
Black RJ, Bray F and Ferlay J et al (1997) Cancer incidence and mortality in the European union. Cancer Registry Data and Estimate of National Incidence for 1990. Eur J Cancer 33: 1075–1107
BMDP (1981). Statistical Software. University of California Press: Berkeley, CA
Carter Eggleston JC (1980), Tumors of the lower respiratory tract. Armed Forces Institute of Pathology
Chute JP, Venzon DJ and Hankins L et al (1997) Outcome of patients with small-cell lung cancer during 20 years of clinical research at the US National Cancer Institute. Mayo Clin Proc 72: 901–912
Chute JP, Chen T and Feigal T et al (1999) Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 17: 1794–1801
Dajczman E, Liyi F, Small D, Wolkove N and Kreisman H (1996) Treatment of small-cell lung carcinoma in the elderly. Cancer 77: 2032–2038
Davis S, Wright PW, Schulman SF, Scholes D, Thorning D and Hammar S (1985) Long-term in small-cell carcinoma of the lung: a population experience. J Clin Oncol 3: 80–91
Dearing MP, Steinberg SM and Phelps R et al (1990) Outcome of patients with small-cell lung cancer: effect of changes in staging procedures and imaging technology on prognostic factors over 14 years. J Clin Oncol 8: 1042–1049
European Bureau for Action on Smoking Prevention (1990) Europe for smoking prevention. Newsletter 8,
Engeland A, Bjorge T and Haldorsen T Tretlis (1998) Prognosis of patients with lung cancer diagnosed in Norway, 1954–93. Cancer Causes Control 9: 57–65
Evans WK, Sheperd FA and Osoba D et al (1985) VP16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol 3: 1471–1447
Feinstein AR, Sosin DM and Well CK (1985) The Will Rogers Phenomenon: stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 312: 1604–1608
Fox W and Scadding JG Medical Research Council (1973) Comparative trial of surgery and radiotherapy for primary treatment of small-cell or oat-celled carcinoma of the bronchus. Ten years follow-up. Lancet 2: 63–65
Fry WA and Phillips JL et al (1999) Ten-Year Survey of Lung Cancer. Treatment and survival in hospitals in the United States. A National Cancer Data Base Report. Cancer 86: 1867–1876
Fukuoka M, Furuse K and Saijo N et al (1991) Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 83: 855–861
Giaccone G, Donadio M and Bonardi G et al (1988) Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy. J Clin Oncol 6: 1264–1270
Green RA, Humphrey E and Close H et al (1969) Alkylating agents in bronchogenic carcinoma. Am J Med 46: 516–525
Griffin CA, Lu C and Fishman EK et al (1984) The role of Computed Tomography of the chest in the management of small-cell lung cancer. J Clin Oncol 2: 1359–1365
Hedelin G (1995) Relsurv A program for relative survival. Technical report of the department of epidemiology and public health, Faculty of medicine, Louis Pasteur University, Strasbourg, France,
Humblet Y, Symann M and Bosly A et al (1987) Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study. J Clin Oncol 5: 1864–1873
Insee (1987). Estimation localisée de population,
Janssen-Heijnen MLG, Nab HW and Van Reek J et al (1995) Striking changes in smoking behaviour and lung cancer incidence by histological type in the south-east Netherlands 1960–1991. Eur J Cancer 31A: 949–952
Janssen-Heijnen MLG, Schipper RM and Klinkhamer PJJM et al (1998a) Improvement and plateau in survival of small-cell lung cancer since 1975: a population-based study. Ann Oncol 9: 543–547
Janssen-Heijnen ML, Gatta G, Forman D, Capocaccia R and Coebergh JW (1998b). Variation in survival of patients with lung cancer in Europe, 1985–1989,
Eurocare Working Group Eur J Cancer 34: 2191–2196
Johnson BE and Seth M et al (1988) Female patients with small-cell lung cancer live longer than male patients. Am J Med 85: 194–196
Lassen U, Osterlind K and Hansen M et al (1995) Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18 + Years. An analysis of 1714 consecutive patients. J Clin Oncol 13: 1215–1220
Lebeau B, Chastang C and Schuller MP et al (1995) Chimiothérapie des cancers bronchiques à petites cellules. Importance pronostique d’une réponse complète (1280 patients). La Presse Medicale 24: 217–221
Livingston RM, Moore TN and Heilbrun L et al (1978) Small cell carcinoma of the lung: combined chemotherapy and radiation. A Southwest Oncology Group Study. Ann Intern Med 88: 194–199
Maestu I, Pastor M and Gomez-Codina J et al (1997) Pretreatment prognostic factors for survival in small-cell lung cancer: a new prognostic index and validation of three new prognostics indices on 341 patients. Ann Oncol 8: 547–553
Maurer LH and Pajak TF (1981) Prognostic factors in small-cell carcinoma of the lung: a Cancer and Leukemia Group B Study. Cancer Treat Rep 65: 767–774
Osterlind K and Andersen PK (1986) Prognostic factor in small-cell lung cancer: multivariate model based on 778 patients treated with chemotherapy with or without irradiation. Cancer Res 46: 4189–4194
Paesmans M, Mascaux C and Berghmans T et al (1999) Etoposide and cisplatin merit their key role in chemotherapy for small-cell lung cancer: a meta-analysis with a methodology assessment, by the European Lung Cancer Working Party (ELCWP). Am Soc Clin Oncol 18: 474a
Parkin DM, Ferlay J and Pisani P (1993) Estimate of the worldwide incidence of eighteen major cancers in 1985. Intern J Cancer 54: 594–606
Perry MC and Eaton WL et al (1987) Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. N Engl J Med 316: 912–918
Pignon JP, Arriagada R and Ihde D et al (1992) A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 327: 1618–1624
Pujol JL & Carestia Daures JP (2000a) Is there a case of cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer 83: 8–15
Pujol JL (2000b) Doublet etoposide-cisplatin versus quadruplet cisplatin-cyclophosphamide-epirubicin-etoposide in extensive disease small-cell lung cancer. A FNCLCC Phase III multicentric study. Proc ASCO 19: 484a
Quoix E, Finkelstein H, Wolkove N and Kreisman H (1986) Treatment of small-cell lung cancer on protocol: potential bias of results. J Clin Oncol 4: 1314–1320
Quoix E, Purohit A and Faller-Beau M et al (2000) Comparative prognostic value of lactate dehydrogenase and neuron-specific enolase in small-cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer 30: 127–134
Rawson NSB and Peto J (1990) An overview of prognostic factors in small-cell lung cancer. Br J Cancer 61: 597–604
Roth BJ, Johnson DH and Einhorn LH et al (1992) Randomized study of cyclophosphamide, doxorubicine, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 10: 282–291
Sagman U, Maki E and Evans WK et al (1991) Small-cell carcinoma of the lung: derivation of a prognostic staging system. J Clin Oncol 9: 1639–1649
Schwartz D (1996). Méthodes statistiques à l’usage des Médecins et des Biologistes, 4ème ed
Silverberg E (1998). Cancer statistics 1988: a cancer Journal for Clinicians 38: 5–22
Souhami R, Geddes DM and Spiro SG et al (1984) Radiotherapy in small-cell of the lung treated with combination chemotherapy: a controlled trial. BMJ 288: 1643–1656
Spiegelman D, Maurer LH and Ware LH et al (1989) Prognostic factors in small cell carcinoma of the lung: an analysis of 1521 patients. J Clin Oncol 7: 344–354
(1995). Statxact 3 for Windows by Cyrus Metha and Nitin Patel, Founders of Cytel Software Corporation. Cambridge, MA 02139
Trumble EL, Carer CL, Cain D, Freindlin D, Ungecleider RS and Friedman MA (1994) Representation of older patients in cancer treatment trials. Cancer 74: 2208–2214
Warde P and Payne D (1992) Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung. J Clin Oncol 10: 890–895
Wolf M, Holle R and Hans K et al (1991) Analysis of prognostic factors in 766 patients with small-cell lung cancer (SCLC): the role of sex as a predictor of survival. Br J Cancer 63: 986–992
World Health Organization (1998). Histological typing of tumors. 3rd ed., Geneva
Zelen M (1973) Keynote Address on Biostatistics and Data Retrieval. Cancer Chemother Rep 4: 31–42
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Lebitasy, M., Hédelin, G., Purohit, A. et al. Progress in the management and outcome of small-cell lung cancer in a French region from 1981 to 1994. Br J Cancer 85, 808–815 (2001). https://doi.org/10.1054/bjoc.2001.1955
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1054/bjoc.2001.1955
Keywords
This article is cited by
-
Bevacizumab-containing chemotherapy for non-small cell lung cancer patients: a population-based observational study by the Ibaraki thoracic integrative (POSITIVE) research group
Medical Oncology (2012)
-
A population-based study of gefitinib in patients with non-small cell lung cancer
Medical Oncology (2009)
-
Le cancer bronchique du sujet âgé
Oncologie (2008)
-
International comparisons of survival from lung cancer: pitfalls and warnings
Nature Clinical Practice Oncology (2007)
-
Time and chemotherapy treatment trends in the treatment of elderly patients (age ⩾70 years) with small cell lung cancer
British Journal of Cancer (2006)
